WO2001030390A2 - Method - Google Patents
Method Download PDFInfo
- Publication number
- WO2001030390A2 WO2001030390A2 PCT/EP2000/010733 EP0010733W WO0130390A2 WO 2001030390 A2 WO2001030390 A2 WO 2001030390A2 EP 0010733 W EP0010733 W EP 0010733W WO 0130390 A2 WO0130390 A2 WO 0130390A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- polysaccharide
- dose
- infant
- administered
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This immunological phenomenon changes (and is made less predictable) when a polysaccharide conjugate vaccine is made (for instance by conjugating the polysaccharide antigen to a peptide or protein which provides T-helper epitopes), as there are now 2 elements to the immune response, a B-cell element related to the polysaccharide, and a T-cell element related to the carrier protein.
- a polysaccharide conjugate vaccine for instance by conjugating the polysaccharide antigen to a peptide or protein which provides T-helper epitopes
- the present invention provides method of determining the dose response of a human (preferably humans aged from a few days old to one year) to a polysaccharide conjugate vaccine comprising an immunogenic carrier protein and a bacterial polysaccharide, said method comprising the steps of administering to an infant animal a dose amount of said conjugated vaccine, and determining the immune response of the animal to the bacterial polysaccharide as a measure of the immune response of a human.
- Preferred modes of administration of vaccine in the model, dose of vaccine tested, time between doses, time of serum harvesting, method of determination of immune response, and type (and age) of infant animal used are all provided.
- FIG. 1 Geometric Mean IgG Concentration in Costa Rican Infants 1 month after the third injection of a Tetravalent pneumococcal PS-PD vaccine (comprising serotypes 6B, 14, 19F and 23F, and aluminium phosphate adjuvant). Bars indicate the 95% confidence interval.
- FIG. 1 Geometric Mean IgG Concentration in Infant Rats 1 month after the third injection of a Tetravalent pneumococcal PS-PD vaccine with aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- Figure 4. Geometric Mean IgG Concentration in Infant Rats 2 weeks after the third injection of an 11-valent pneumococcal PS-PD vaccine also containing aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- FIG. 1 Geometric Mean IgG Concentration in Infant mice (first injection when they were 2 days old) 2 weeks after the third injection of an 11-valent pneumococcal PS-PD vaccine also containing aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- FIG. 7 Geometric Mean IgG Concentration in Infant mice (first injection when they were 1 week old) 2 weeks after the third injection of an 11-valent pneumococcal PS-PD vaccine also containing aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- FIG. 1 Geometric Mean IgG Concentration in Infant mice (first injection when they were 2 weeks old) 2 weeks after the third injection of an 11-valent pneumococcal PS-PD vaccine also containing aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- FIG. 9 Geometric Mean IgG Concentration in Infant mice (first injection when they were 4 weeks old) 2 weeks after the third injection of an 11-valent pneumococcal PS-PD vaccine also containing aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- FIG. 10 Geometric Mean IgG Concentration in young mice (first injection when they were 8 weeks old) 2 weeks after the third injection of an 11-valent pneumococcal PS-PD vaccine also containing aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- Figure 11. Geometric Mean IgG Concentration in Infant Rhesus Monkeys 1 month after the third injection of a tetravalent pneumococcal PS-PD vaccine with aluminium phosphate adjuvant. Bars indicate the 95% confidence interval.
- FIG. 12 Comparisons of anti-pneumococcal PS IgG titre in infant mice (4 weeks old at first injection) injected with the pneumococcal PS conjugate vaccine sub- cutaneously (SC) vs. humans injected intra-muscularly (IM), and in infant mice (4 weeks old at first injection) injected with the pneumococcal PS conjugate vaccine intra-muscularly vs. humans injected intra-muscularly.
- the vaccine was administered 3 times with 2 weeks between injections. Serum was collected 2 weeks after the third injection.
- ELISA tests were carried our as described in Examples.
- a new, improved method in which an animal model can be used to make a predictive correlation between the dosage response in the model and the response in humans.
- the invention thereby provides an animal model that correctly reflects human immunogenicity to conjugate vaccines.
- Such a model will be extremely useful for the lot release testing of vaccines. It will also be an important preclinical research tool for designing and evaluating new vaccine compositions (formulations with new combinations of antigens, new dosages of antigens or new excipients or adjuvants) without having to carry out as many human trials as was required previously.
- the present inventors have found that different animal models give different dose-response curves (the relationship between Geometric Mean Concentration of IgG antibodies against an antigen [the polysaccharide antigen in polysaccharide conjugate vaccines] and the dose of vaccine administered with a given injection schedule) with no clear indication of which animal model is predictive of human data. It was found that only infant animals showed the strong inverse dose-response (high dose tolerance) that was demonstrated later for some serotypes in human infants.
- the use of infant mice in such experiments matched the human infant data best given a certain correction factor -the dosage giving the maximum response in the infant mouse is at approximately 1/10 the human dosage (the dose-response curves in general also being comparable between infant mice and humans given this corrective factor).
- one aspect of the present invention provides a method of determining the dose response (as described above) of a human to an antigen, said method comprising the steps of administering to an infant animal a dose amount of said antigen, and determining the immune response of the animal to the antigen as a measure of the immune response of a human (preferably humans from birth to 1 year).
- antigen e.g. protein, nucleic acid or carbohydrate - or combinations thereof.
- polysaccharide conjugate vaccines comprising an immunogenic carrier protein and a bacterial polysaccharide because of the especially unpredictable nature of the immune response against these antigens as described above.
- the response to the polysaccharide portion of the vaccine may be predicted. From this point onwards it should be understood that the methods involving 'polysaccharide conjugate vaccines' are envisaged also to be applicable to any type of antigen.
- the inventors have found that the polysaccharide conjugate vaccine should advantageously be administered to the infant animals intramuscularly (rather than, for instance, sub-cutaneously), as the relative immunogenicity of the polysaccharide component correlates better still with data from human trials.
- the dose of vaccine administered to the infant animal should range from 0.001-10 ⁇ g, and most preferably from 0.01-1 ⁇ g.
- Reference to amounts of polysaccharide conjugate antigen in this specification always refers to the dosage of the polysaccharide component only (independent of amount of carrier). One or more doses may be chosen from this range. The more dosage points chosen, the more information the dose response curve will yield.
- the vaccine is administered to the infant animal the same number of times as the administration protocol of the human vaccine. Therefore, for a human polysaccharide conjugate vaccine which is to be administered in a three dose schedule, when tested in the model of the invention, each animal should similarly be injected with the vaccine three times. Furthermore, if the human vaccine involves the administration of 2 doses of conjugated polysaccharide and one dose of unconjugated polysaccharide, preferably the test in the model of the invention should be carried out likewise.
- a serum sample is collected from the infant animals for testing 1-4 weeks after the last dose of vaccine is administered (and most preferably after approximately 2 weeks).
- a preferred method of determining the response in the animal model to the vaccine is by measuring the concentration of anti-polysaccharide antibody in the infant animal serum per dose of vaccine administered by ELISA. This can be quite accurately done if all ELISA tests are calibrated with purified antibodies (preferably monoclonal antibodies) against the polysaccharide antigen.
- the method of transposing the infant animal data into a predicted dose response in humans is by using a dose conversion factor.
- Infant animals (particularly infant mice) will exhibit a similar dose response curve to humans, but at approximately 1/10 of the dose for each measurement.
- a dose conversion factor for pre-clinical research purposes, it is envisaged that for a given concentration of anti-polysaccharide antibody in the infant animal serum per dose of vaccine administered, approximately the same anti-polysaccharide response is seen in humans (particularly from birth to 1 year) at 5-20 times (preferably about 10 times) the dose administered to the infant animal.
- human data will have been collected, and a more precise conversion factor can be ascertained from the human data available.
- the infant animals may be rats, Rhesus monkey, chinchilla, rabbits, guinea pigs or mice.
- the infant animals may not be humans.
- the time in which animals are in their infancy can vary, however in general the age of the infant animals at the time of first inoculation should be between 1 day and 12 weeks, more preferably 2 days and 8 weeks, and most preferably 2-4 weeks.
- the first inoculation should preferably be between 1 day and 6-8 weeks, more preferably between 2 days and 5 weeks, still more preferably between 2-4 weeks, and most preferably around 4 weeks old.
- the above method is carried out with infant mice. Most preferably Balb/c infant mice. This model has been shown for the first time to be particularly suited to predicting human (preferably from birth to 1 year) dose response curves for polysaccharide conjugate vaccines.
- the infant mouse is 2 days to 8 weeks old at the time of first inoculation, and most preferably about 4 weeks old at the time of first inoculation.
- Any type of bacterial polysaccharide conjugates can be used in the above method - in particular where the bacterial polysaccharide component is selected from a group consisting of: a PRP capsular polysaccharide from H.
- influenzae type B a capsular polysaccharide from Streptococcus pneumoniae; a capsular polysaccharide from Group B Streptococcus; a capsular polysaccharide from Group A Streptococcus; a capsular polysaccharide from meningococcus serogroup A; a capsular polysaccharide from meningococcus serogroup Y; a capsular polysaccharide from meningococcus serogroup W-135; a capsular polysaccharide from meningococcus serogroup C; and the Ni polysaccharide from Salmonella typhi.
- the polysaccharide is the capsular polysaccharide from any strain of Streptococcus pneumoniae (most preferably from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9 ⁇ , 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, or 33F).
- the carrier protein used to conjugate the polysaccharide to may be a peptide or a polypeptide, but should be a provider of T-helper epitopes. Any of those commonly used in the art may be used. Typical examples are diphtheria toxoid; CRM197; tetanus toxoid; inactivated or mutant pneumococcal pneumolysin; or meningococcal OMPC.
- the protein is H. influenzae protein D (see EP 594610-B).
- a further aspect of the present invention provides a use of infant animals as a method of determining the dose response of a human (preferably from birth to 1 year) to a polysaccharide conjugate vaccine comprising an immunogenic carrier protein and a bacterial polysaccharide (particularly via the methods detailed above).
- the present inventors have revealed that for many pneumococcal polysaccharide conjugates, the immune response is not directly related to dose, but is bell-shaped - with the highest doses (usually 25 ⁇ g of polysaccharide are used in current unconjugated vaccines) and lowest doses yielding a lesser immune response than intermediate doses.
- the dose response curve is more of a plateau in nature.
- the present inventors have tested various doses of pneumococcal polysaccharide conjugate vaccines to determine which dose is optimal for a particular polysaccharide conjugate.
- Optimal responses for the various polysaccharide conjugates in the infant mouse model could be converted to optimal human doses.
- These optimal human doses were found to be at either a low, medium or high dose.
- a low dose is defined to be between 0.01 ⁇ g and 2.5 ⁇ g, and is preferably between 0.05 and 2 ⁇ g, and most preferably 1 ⁇ g of each conjugate (as mentioned above, reference to amounts of polysaccharide conjugate antigen refers to the dosage of the polysaccharide component only).
- a medium dose is defined to be between 2.5 ⁇ g and 4.5 ⁇ g, and is preferably between 2.6 and 4 ⁇ g, and most preferably 3 ⁇ g of each conjugate.
- a high dose is defined to be between 4.5 ⁇ g and 10 ⁇ g, and is preferably between 5 and 8 ⁇ g, and most preferably 6 ⁇ g of each conjugate.
- eleven valent pneumococcal polysaccharide conjugate vaccine (which may be conjugated to any immunogenic protein, preferably those described above, and most preferably protein D) the following has been found:
- PS 1 and 3 have optimal doses between a medium and a high dose.
- the present inventors have found that by having the correct dose of conjugate in a vaccine, the resulting response can be improved up to 3 times than when the conjugate is dosed at a non-optimal level. Such increases in antibody titre can be related to larger proportions of the immunised population eliciting a protective immune response against the antigen. Properly dosed vaccines are thus highly advantageous.
- a further aspect of the invention is thus a pneumococcal polysaccharide conjugate vaccine comprising one or more pneumococcal capsular polysaccharide conjugate antigens derived from serotypes 6B, 19F or 23F, and is present at a low dose in the vaccine.
- pneumococcal polysaccharide conjugate vaccine comprising one or more pneumococcal capsular polysaccharide conjugate antigens derived from serotypes 1, 3, 5, 7F or 18C, and is present at a medium dose in the vaccine.
- a still further embodiment of the invention is a pneumococcal polysaccharide conjugate vaccine comprising one or more pneumococcal capsular polysaccharide conjugate antigens derived from serotypes 1, 3, 4, 9N or 14, and is present at a high dose in the vaccine.
- pneumococcal polysaccharide conjugate vaccines may be combined in a single vaccine, a combination vaccine comprising 2 or more pneumococcal capsular polysaccharide conjugate antigens at an optimal concentration for inducing an optimal anti-polysaccharide antibody response when administered to a human is also envisaged.
- one or more of the pneumococcal capsular polysaccharide conjugate antigens is derived from serotypes 6B, 19F or 23F, and is present at a low dose in the vaccine.
- one or more of the pneumococcal capsular polysaccharide conjugate antigens may be derived from serotypes 1, 3, 5, 7F or 18C, and be present at a medium dose in the vaccine.
- one or more of the pneumococcal capsular polysaccharide conjugate antigens may be derived from serotypes 1, 3, 4, 9V or 14, and be present at a high dose in the vaccine.
- a particularly preferred combination vaccine comprises conjugate antigens derived from serotypes 6B, 19F and 23F present at a low dose, conjugate antigens derived from serotypes 1, 3, 5, 7F and 18C present at a medium dose, and conjugate antigens derived from serotypes 4, 9N and 14 present at a high dose in the vaccine.
- serotypes 1 and/or 3 may be present in the combination at a high dose.
- a further embodiment of the invention is a vaccine comprising one of the above pneumococcal polysaccharide conjugate vaccines of the invention in combination with one or more of the following polysaccharide conjugates where the bacterial polysaccharide component is selected from a group consisting of: a PRP capsular polysaccharide from H.
- influenzae type B a capsular polysaccharide from Group B Streptococcus; a capsular polysaccharide from Group A Streptococcus; a capsular polysaccharide from meningococcus serogroup A; a capsular polysaccharide from meningococcus serogroup Y; a capsular polysaccharide from meningococcus serogroup W-135; and a capsular polysaccharide from meningococcus serogroup C.
- a combination vaccine comprising the pneumococcal polysaccharide conjugate vaccine of the invention, a PRP conjugate and one or more of the aforementioned meningococcal polysaccharide conjugates is especially advantageous for use as a global vaccine against meningitis.
- most (and preferably all) of the polysaccharide conjugates are present in the vaccine at their optimal dose (as determinable by the above methods).
- the above polysaccharide conjugates are conjugated to any of the aforementioned protein carriers, preferably protein D.
- all polysaccharides may be conjugated to the same carrier, this need not be the case. They may be individually conjugated to different carriers and combined so as to minimise possible carrier immune suppression that is sometimes observed where too much of a single carrier is used in a combination vaccine.
- the vaccines of the invention are for use in human infants (particularly from birth to 1 year).
- the vaccine compositions of the invention may be formulated with an adjuvant such as alum or 3D-MPL.
- an adjuvant such as alum or 3D-MPL.
- 3D-MPL devoid of aluminium adjuvant is used (as described in WO 00/56358).
- Other commonly used excipients may also be used.
- S.pneumoniae capsular polysaccharide The tetravalent vaccine includes the capsular polysaccharides from serotypes 6B, 14, 19F and 23F.
- the 11 -valent candidate vaccine includes the capsular polysaccharides from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F which were made essentially as described in EP 72513.
- Each polysaccharide is activated and derivatised using CDAP chemistry (WO 95/08348) and conjugated to the protein carrier. All the polysaccharides are conjugated in their native form, except for the serotype 3. It was reduced in molecular size.
- the protein carrier selected is the recombinant protein D (PD) from Non typeable Haemophilus influenzae, expressed in E. coli.
- PD recombinant protein D
- Example 2 A review of the literature of pneumococcal conjugate vaccines showed it was not possible to make a clear correlation between the dosage response in animal models and the dosage response in humans. Furthermore, while different trends were reported in the literature for the various pneumococcal conjugates (bell-shaped, decreasing, and flat), the lack of statistical data made it impossible to determine if any of these were significantly different.
- the data from the dosage-response studies undertaken in 6 animal models with the protein D conjugate vaccine was assessed in order to observe the animal model(s) that best matched the human data from the dosage response study TetraPn005 in infant humans in Costa Rica. The assessment was done by blinding the assessors to the particular animal model. Those tested were adult and infant rat and mouse, infant Rhesus monkey, and adult chinchilla.
- the ELISA was performed to measure serum IgG using the WHO/CDC consensus procedure for the quantitation of IgG antibody against Streptococcus pneumoniae capsular polysaccharides.
- purified capsular polysaccharide is coated directly on the microtitre plate.
- Serum samples are pre-incubated with the cell- wall polysaccharide common to all pneumococcus and which is present in ca. 0.5% in pneumococcal polysaccharides purified according to disclosure (EP72513 Bl).
- Jackson ImmunoLaboratories Inc. reagents were employed to detect bound IgG.
- the titration curves were referenced logistic log equation to internal standards (monoclonal antibodies).
- the calculations were performed using SoftMax Pro software. The maximum absolute error on these results expected to be within a factor of 2. The relative error is less than 30%.
- Figures 2 to 6, 10 and 11 were analysed to identify which animal model corresponded best with the human dosage response curves (Fig. 2).
- the animal models were blinded, but included adult and infant rats, adult and infant mice, and infant Rhesus. In addition, adult Chinchilla data were analysed. Mice of 1, 2, and 4 weeks were not included.
- mice groups were studied which were first immunised (sub- cutaneously) at 2 days old, and 1, 2, 4 and 8 weeks of age. Three immunisations took place (at day 0, 14 and 28) with 50 ⁇ l of 11 -valent pneumococcal polysaccharide conjugate vaccine containing either 0.01, 0.1 or 0.5 ⁇ g per polysaccharide with 50 ⁇ g aluminium phosphate as adjuvant. A final bleed was taken at day 42. Taking into consideration the 95% confidence intervals, which may hide the true dosage-response curve, the 4 week old mouse has the best match with the human data. This is because the response to 6B is far too low to be realistic in younger mice. Note that sometime between 2 and 4 weeks of age, the mice obtain the ability to mount a higher response to 6B. This reduced immunogenicity to 6B is possibly related to the fact that antibodies to it may cross-react with double stranded DNA.
- a bell-shaped dosage-response curve has been observed with some pneumococcal polysaccharide conjugate serotypes in both humans and animal models. Other serotypes show a plateau dosage response curve. Humans under 1 year have a maximum response at approximately 1-10 ⁇ g, and infant mice have a maximum between 0.1 and 1 ⁇ g. In general the mice appear to respond in a similar way at about 1/10 the human dose.
- Figure 12 shows comparisons of anti-pneumococcal PS IgG titre in infant mice (4 weeks old at first injection) injected with the 11 valent pneumococcal PS conjugate vaccine sub-cutaneously vs. humans injected intra-muscularly, and in infant mice (4 weeks old at first injection) injected with the 11 valent pneumococcal PS conjugate vaccine intra-muscularly vs. humans injected intra-muscularly.
- the vaccine was administered 3 times with 2 weeks between injections. Serum was collected 2 weeks after the third injection.
- ELISA tests were carried our as described above. As can be seen, intra-muscular administration of the vaccine in mice results in a further improvement to the model.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002388995A CA2388995A1 (en) | 1999-10-28 | 2000-10-27 | Method |
AU18549/01A AU1854901A (en) | 1999-10-28 | 2000-10-27 | Novel method |
EP00981226A EP1223987A2 (en) | 1999-10-28 | 2000-10-27 | Method |
JP2001532807A JP2003512440A (en) | 1999-10-28 | 2000-10-27 | New method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9925559.8 | 1999-10-28 | ||
GBGB9925559.8A GB9925559D0 (en) | 1999-10-28 | 1999-10-28 | Novel method |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10111521 A-371-Of-International | 2002-08-02 | ||
US10/818,819 Continuation US20040191834A1 (en) | 1999-10-28 | 2004-04-06 | Novel method |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001030390A2 true WO2001030390A2 (en) | 2001-05-03 |
WO2001030390A3 WO2001030390A3 (en) | 2002-04-04 |
Family
ID=10863574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010733 WO2001030390A2 (en) | 1999-10-28 | 2000-10-27 | Method |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1223987A2 (en) |
JP (1) | JP2003512440A (en) |
AU (1) | AU1854901A (en) |
CA (1) | CA2388995A1 (en) |
GB (1) | GB9925559D0 (en) |
WO (1) | WO2001030390A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1296715A2 (en) | 2000-06-29 | 2003-04-02 | Smithkline Beecham Biologicals S.A. | Multivalent vaccine composition |
JP2005535298A (en) * | 2002-05-15 | 2005-11-24 | ルシアーノ ポロネリ, | Glucan based vaccine |
WO2008028956A1 (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
WO2009104097A2 (en) | 2008-02-21 | 2009-08-27 | Novartis Ag | Meningococcal fhbp polypeptides |
WO2010070453A2 (en) | 2008-12-17 | 2010-06-24 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
EP2258717A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Variant form of meningococcal NadA |
EP2263688A1 (en) | 2001-06-20 | 2010-12-22 | Novartis AG | Neisseria meningitidis combination vaccines |
EP2267036A1 (en) | 2003-10-02 | 2010-12-29 | Novartis Vaccines and Diagnostics S.r.l. | Hypo- and Hyper-Acetylated Meningococcal Capsular Saccharides |
EP2277538A1 (en) | 2003-10-02 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
EP2289546A2 (en) | 2003-01-30 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
WO2011024072A2 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
EP2336147A3 (en) * | 2003-12-17 | 2011-07-27 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
EP2351579A1 (en) | 2002-10-11 | 2011-08-03 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
EP2385126A1 (en) | 2005-11-25 | 2011-11-09 | Novartis Vaccines and Diagnostics S.r.l. | Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
EP2462949A2 (en) | 2007-10-19 | 2012-06-13 | Novartis AG | Meningococcal vaccine formulations |
CN102507924A (en) * | 2011-11-17 | 2012-06-20 | 成都欧林生物科技股份有限公司 | Method for detecting concentration of polysaccharide in zymotic fluid |
WO2012153302A1 (en) | 2011-05-12 | 2012-11-15 | Novartis Ag | Antipyretics to enhance tolerability of vesicle-based vaccines |
US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
WO2013113917A1 (en) | 2012-02-02 | 2013-08-08 | Novartis Ag | Promoters for increased protein expression in meningococcus |
EP2659912A2 (en) | 2007-07-17 | 2013-11-06 | Novartis AG | Conjugate purification |
EP2682127A1 (en) | 2007-05-02 | 2014-01-08 | GlaxoSmithKline Biologicals S.A. | Vaccine |
US8722062B2 (en) | 2001-01-23 | 2014-05-13 | Sanofi Pasteur, Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
US10543265B2 (en) | 2006-03-22 | 2020-01-28 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604108A (en) * | 1992-09-14 | 1997-02-18 | Connaught Laboratories, Inc. | Test for determining the dose response of a conjugated vaccine |
WO1999033488A2 (en) * | 1997-12-24 | 1999-07-08 | Smithkline Beecham Biologicals S.A. | Adjuvanted vaccine formulation |
WO2000056358A2 (en) * | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccine against streptococcus pneumoniae capsular polysaccharides |
-
1999
- 1999-10-28 GB GBGB9925559.8A patent/GB9925559D0/en not_active Ceased
-
2000
- 2000-10-27 JP JP2001532807A patent/JP2003512440A/en active Pending
- 2000-10-27 AU AU18549/01A patent/AU1854901A/en not_active Abandoned
- 2000-10-27 WO PCT/EP2000/010733 patent/WO2001030390A2/en not_active Application Discontinuation
- 2000-10-27 EP EP00981226A patent/EP1223987A2/en not_active Withdrawn
- 2000-10-27 CA CA002388995A patent/CA2388995A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604108A (en) * | 1992-09-14 | 1997-02-18 | Connaught Laboratories, Inc. | Test for determining the dose response of a conjugated vaccine |
WO1999033488A2 (en) * | 1997-12-24 | 1999-07-08 | Smithkline Beecham Biologicals S.A. | Adjuvanted vaccine formulation |
WO2000056358A2 (en) * | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccine against streptococcus pneumoniae capsular polysaccharides |
Non-Patent Citations (7)
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2277541A1 (en) * | 2000-06-29 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | Multivalent vaccine composition |
EP1296715A2 (en) | 2000-06-29 | 2003-04-02 | Smithkline Beecham Biologicals S.A. | Multivalent vaccine composition |
US9844601B2 (en) | 2001-01-23 | 2017-12-19 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US9173955B2 (en) | 2001-01-23 | 2015-11-03 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US8999354B2 (en) | 2001-01-23 | 2015-04-07 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US8741314B2 (en) | 2001-01-23 | 2014-06-03 | Sanofi Pasteur, Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US8734813B2 (en) | 2001-01-23 | 2014-05-27 | Sanofi Pasteur, Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US8722062B2 (en) | 2001-01-23 | 2014-05-13 | Sanofi Pasteur, Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US10143757B2 (en) | 2001-01-23 | 2018-12-04 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US10617766B2 (en) | 2001-01-23 | 2020-04-14 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US8889152B2 (en) | 2001-06-20 | 2014-11-18 | Novartis Ag | Capsular polysaccharides solubilisation and combination vaccines |
EP2277537A2 (en) | 2001-06-20 | 2011-01-26 | Novartis AG | Neisseria meningitidis conjugate combination vaccine |
EP2277539A2 (en) | 2001-06-20 | 2011-01-26 | Novartis AG | Neisseria meningitidis conjugate combination vaccine |
US9782467B2 (en) | 2001-06-20 | 2017-10-10 | Glaxosmithkline Biologicals Sa | Capsular polysaccharide solubilisation and combination vaccines |
US8852606B2 (en) | 2001-06-20 | 2014-10-07 | Novartis Ag | Capsular polysaccharide solubilisation and combination vaccines |
US9782466B2 (en) | 2001-06-20 | 2017-10-10 | Glaxosmithkline Biologicals Sa | Capsular polysaccharide solubilisation and combination vaccines |
US10716841B2 (en) | 2001-06-20 | 2020-07-21 | Glaxosmithkline Biologicals Sa | Capsular polysaccharide solubilisation and combination vaccines |
US8753651B2 (en) | 2001-06-20 | 2014-06-17 | Novartis Ag | Capsular polysaccharide solubilisation and combination vaccines |
US9358278B2 (en) | 2001-06-20 | 2016-06-07 | Novartis Ag | Capsular polysaccharide solubilisation and combination vaccines |
US9452207B2 (en) | 2001-06-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Capsular polysaccharide solubilisation and combination vaccines |
EP2263688A1 (en) | 2001-06-20 | 2010-12-22 | Novartis AG | Neisseria meningitidis combination vaccines |
EP2277536A2 (en) | 2001-06-20 | 2011-01-26 | Novartis AG | Purification of bacterial capsular polysaccharides |
JP2005535298A (en) * | 2002-05-15 | 2005-11-24 | ルシアーノ ポロネリ, | Glucan based vaccine |
EP2351579A1 (en) | 2002-10-11 | 2011-08-03 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
EP2353608A1 (en) | 2002-10-11 | 2011-08-10 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
EP2258717A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Variant form of meningococcal NadA |
EP2258716A2 (en) | 2002-11-22 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
EP2261239A2 (en) | 2002-11-22 | 2010-12-15 | Novartis Vaccines and Diagnostics S.r.l. | Multiple variants of meningococcal protein NMB1870 |
US10272147B2 (en) | 2003-01-30 | 2019-04-30 | Glaxosmithkline Biologicals S.A. | Injectable vaccines against multiple meningococcal serogroups |
EP2289546A2 (en) | 2003-01-30 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
US9981031B2 (en) | 2003-01-30 | 2018-05-29 | Glaxosmithkline Biologicals Sa | Injectable vaccines against multiple meningococcal serogroups |
EP2277538A1 (en) | 2003-10-02 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
EP2267036A1 (en) | 2003-10-02 | 2010-12-29 | Novartis Vaccines and Diagnostics S.r.l. | Hypo- and Hyper-Acetylated Meningococcal Capsular Saccharides |
US8227403B2 (en) | 2003-12-17 | 2012-07-24 | Wyeth Llc | A-β immunogenic peptide carrier conjugates and methods of producing same |
US9125847B2 (en) | 2003-12-17 | 2015-09-08 | Janssen Sciences Ireland Uc | A-β immunogenic peptide carrier conjugates and methods of producing same |
EP2336147A3 (en) * | 2003-12-17 | 2011-07-27 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
US9095536B2 (en) | 2003-12-17 | 2015-08-04 | Janssen Sciences Ireland Uc | Aβ immunogenic peptide carrier conjugates and methods of producing same |
US9089510B2 (en) | 2003-12-17 | 2015-07-28 | Janssen Sciences Ireland Uc | A-β immunogenic peptide carrier conjugates and methods of producing same |
EP2479184A3 (en) * | 2003-12-17 | 2013-09-04 | Janssen Alzheimer Immunotherapy | Beta immunogenic peptide carrier conjugates and methods of producing the same |
US10245317B2 (en) | 2005-06-27 | 2019-04-02 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US10166287B2 (en) | 2005-06-27 | 2019-01-01 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US8883163B2 (en) | 2005-06-27 | 2014-11-11 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US9486515B2 (en) | 2005-06-27 | 2016-11-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US9789179B2 (en) | 2005-06-27 | 2017-10-17 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US9931397B2 (en) | 2005-06-27 | 2018-04-03 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
US8431136B2 (en) | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US11241495B2 (en) | 2005-06-27 | 2022-02-08 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
EP2385126A1 (en) | 2005-11-25 | 2011-11-09 | Novartis Vaccines and Diagnostics S.r.l. | Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
EP3346009A1 (en) | 2005-11-25 | 2018-07-11 | GlaxoSmithKline Biologicals S.A. | Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870 |
EP2385127A1 (en) | 2005-11-25 | 2011-11-09 | Novartis Vaccines and Diagnostics S.r.l. | Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
US10881721B2 (en) | 2006-03-22 | 2021-01-05 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
US10543265B2 (en) | 2006-03-22 | 2020-01-28 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
WO2008028956A1 (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
EP2682127A1 (en) | 2007-05-02 | 2014-01-08 | GlaxoSmithKline Biologicals S.A. | Vaccine |
US9463250B2 (en) | 2007-07-17 | 2016-10-11 | Glaxosmithkline Biologicals Sa | Conjugate purification |
EP2659912A2 (en) | 2007-07-17 | 2013-11-06 | Novartis AG | Conjugate purification |
EP2462949A2 (en) | 2007-10-19 | 2012-06-13 | Novartis AG | Meningococcal vaccine formulations |
EP3263591A1 (en) | 2008-02-21 | 2018-01-03 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
EP2886551A2 (en) | 2008-02-21 | 2015-06-24 | Novartis AG | Meningococcal fhbp polypeptides |
WO2009104097A2 (en) | 2008-02-21 | 2009-08-27 | Novartis Ag | Meningococcal fhbp polypeptides |
WO2010070453A2 (en) | 2008-12-17 | 2010-06-24 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
EP3017828A1 (en) | 2009-08-27 | 2016-05-11 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
WO2011024072A2 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
WO2012153302A1 (en) | 2011-05-12 | 2012-11-15 | Novartis Ag | Antipyretics to enhance tolerability of vesicle-based vaccines |
CN102507924A (en) * | 2011-11-17 | 2012-06-20 | 成都欧林生物科技股份有限公司 | Method for detecting concentration of polysaccharide in zymotic fluid |
CN102507924B (en) * | 2011-11-17 | 2014-06-18 | 成都欧林生物科技股份有限公司 | Method for detecting concentration of polysaccharide in zymotic fluid |
US9657297B2 (en) | 2012-02-02 | 2017-05-23 | Glaxosmithkline Biologicals Sa | Promoters for increased protein expression in meningococcus |
WO2013113917A1 (en) | 2012-02-02 | 2013-08-08 | Novartis Ag | Promoters for increased protein expression in meningococcus |
Also Published As
Publication number | Publication date |
---|---|
EP1223987A2 (en) | 2002-07-24 |
GB9925559D0 (en) | 1999-12-29 |
AU1854901A (en) | 2001-05-08 |
JP2003512440A (en) | 2003-04-02 |
CA2388995A1 (en) | 2001-05-03 |
WO2001030390A3 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001030390A2 (en) | Method | |
TWI477283B (en) | Immunogenic composition | |
JP3989951B2 (en) | Combined meningitis vaccine | |
Lesinski et al. | Vaccines against polysaccharide antigens | |
JP4162267B2 (en) | Neisseria meningitidis serotype B glycoconjugate and use thereof | |
Shelly et al. | Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults | |
JP4754689B2 (en) | Bacterial meningitis vaccine with multiple oligosaccharide glycoconjugates | |
US6224880B1 (en) | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines | |
US20220118072A1 (en) | Neisseria meningitidis compositions and methods thereof | |
Hennessey Jr et al. | Lessons learned and future challenges in the design and manufacture of glycoconjugate vaccines | |
US6413520B1 (en) | Methods of immunizing adults using anti-meningococcal vaccine compositions | |
US20040191834A1 (en) | Novel method | |
Nurkka et al. | Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children | |
Simonsen et al. | Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly | |
Koskela et al. | Enzyme immunoassay for detection of immunoglobulin G (IgG), IgM, and IgA antibodies against type 6B pneumococcal capsular polysaccharide and cell wall C polysaccharide in chinchilla serum | |
US20220387614A1 (en) | Dosage and administration of a bacterial saccharide glycoconjugate vaccine | |
AU2012203419B2 (en) | Immunogenic composition | |
Vella et al. | Biological activity of Hib conjugates | |
Guirola et al. | Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera | |
DE LA SANTE | RECOMMENDATIONS FOR THE PRODUCTION & CONTROL OF PNEUMOCOCCAL CONJUGATE VACCINES | |
Ruijne et al. | Understanding the Immune Responses to | |
JPH11503525A (en) | Method for binding monosaccharide, oligosaccharide or polysaccharide to solid phase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 532807 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2388995 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000981226 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000981226 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10111521 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000981226 Country of ref document: EP |